Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma: a Randomized, Multicenter, Phase 3 Trial

NCT03700476 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT03700476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03700476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma: a Randomized, Multicenter, Phase 3 Trial
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Unknown status
Start date
December 21, 2018
Completion date
January 31, 2025
Enrollment
425 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal neoplasms